This study focuses on children aged 6 to 12 years with nonsegmental vitiligo, a condition where patches of skin lose their color. The study will test a medication called ruxolitinib cream (also known as Opzelura) compared to a placebo cream. Vitiligo occurs when the body’s immune system attacks and destroys the cells that produce skin color, leading to white patches on the skin.
The purpose of this research is to evaluate how well ruxolitinib cream works in treating children with nonsegmental vitiligo. During the study, participants will apply either ruxolitinib cream or placebo cream to their skin. The treatment will continue for up to 52 weeks, which is approximately one year. The maximum daily amount of cream that can be used is 8.5 grams.
The study will measure how well the treatment works by looking at improvements in the affected skin areas, particularly on the face. The cream is designed for cutaneous use, which means it is applied directly to the skin. Throughout the study, doctors will monitor the participants’ health and any changes in their vitiligo patches to ensure the treatment is safe and effective.
Austria 
Belgium 
Bulgaria 
Denmark 
France 
Germany 
Hungary 
Italy 
Poland 
Portugal 
Spain 
The Netherlands